SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
BJDX

Bluejay Diagnostics, Inc. (NASDAQ:BJDX)

US · Delayed Price · Currency is USD
Healthcare · Medical - Devices
$1.70-$0.10 (-5.56%)
 
Market cap
$1.90M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 10, 2021
Market Cap$1.90M-92.3%
Revenue (ttm)$0
Net Income-$7.68M-12.2%
EPS-$23.48+98.7%
Shares Out1.12M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume22,320
Open$1.71
Previous Close$1.80
Day's Range$1.70 - $1.80
52-Week Range$1.62 - $28.00
Beta0.92
AnalystsHold
Price Targetn/a
Earnings DateMar 23, 2027
-3.89% (1D)
No price history available.

About BJDX

Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.

Address
360 Massachusetts Avenue, Acton, MA, 01720, US
Market Cap
2 million
Employees
6
Industrial Classification
Medical - Devices

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$48.91K
Bought
$221.71K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From BJDX’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-5.56%
5 Days
-36.57%
1 Month
-32.54%
6 Months
-77.86%
1 Year
-92.30%

$BJDX stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in BJDX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by BJDX's directors and management

Net Shares Purchased by Insiders−70k−35k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

BJDX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New BJDX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to BJDX from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from BJDX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
100% of score
29.95
Analyst Ratings
No data yet
—
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
6
Sells
1
Buy Value
$221.71K
Distinct Buyers
6

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.